Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Ares Capital Corporation (ARCC) vs McKesson Corporation (MCK) Price & Performance

Ares Capital CorporationTrade
McKesson CorporationTrade

Price performance (Past 24H)

Key statistics

Ares Capital Corporation vs McKesson Corporation — how do they compare? Ares Capital Corporation trades at $19.96 (market cap $14.34B), while McKesson Corporation trades at $898.01 (market cap $105.14B). The key difference: McKesson Corporation is far larger — about 7.3× Ares Capital Corporation's market cap, and Ares Capital Corporation pays the higher dividend (9.61%). Which is the better fit depends on your goals.

ARCCMCK
Market Cap
$14.34B$105.14B
Sector
FinancialsHealth
52-Week High
$22.68$995.69
52-Week Low
$17.45$659.01
Dividend Yield
9.61%0.42%
Enterprise Value
$111.67B

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Ares Capital Corporation

Ares Capital Corp is a United States-based closed-ended specialty finance company. Its investment objective is to generate both current income and capital appreciation through debt and equity investments. The company focuses on investing primarily in U.S. middle-market companies with investment opportunities as well as in larger companies. Its portfolio comprises of first lien senior secured loans, second lien senior secured loans, and mezzanine debt (subordinated unsecured loan), which may include equity components that are diversified by industry and sector. The company may invest in preferred and common equity investments to a lesser proportion. Its revenue mainly consists of interest and dividend income received from the investment made.

Read more on ARCC

About McKesson Corporation

McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.

Read more on MCK